Ranibizumab Inhibits Human Tenon’s Fibroblast Proliferation via p21 Dependent p53 Mechanisms

Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention failed. In a trabeculectomy, number of clinical trials have shown efficacy ranibizumab minimizing extracellular matrix accumulation at filtering site. Ranibizumab (LucentisTM) drug that targets vascular endothelial growth factor (VEGF). However, to date actual mechanisms this anti-VEGF trabeculectomy still not well understood. Hence, here we aimed elucidate effects on human Tenon’s fibroblast (HTF) isolated from patients undergoing trabeculectomy. our previous study, had reported reduces level spermidine metabolite whereby an important polyamine for cell proliferation. For current cultured HTFs were divided into untreated, control IgG, only, difluoromethylornithine (DFMO; inhibitor spermidine) only with DFMO. All cells extracted PCR array (expression CDKN1A, CDK2, CDK4) protein expression p53, p21, CDK4 by Western Blot. here, result demonstrated treated or DFMO ranibizumab-DFMO similar as both show increased p53 p21. Meanwhile, no significant differences CDK2 observed all groups. essence, findings suggest action mediated p21 p53.